tbuckley/cabot-search huggingface dataset:
Prevalence of smoking in cancer survivors: National Health and Nutrition Examination Survey (NHANES) III data analysis.
Authors: Mohammed Shaik, Peter C. Kurniali, Mohammad Omaira, Mohamed Wajih Akkad, Anas Al-Janadi, Borys Hrinczenko
Journal: Journal of Clinical Oncology (2014)

1575 Background: Smoking is an important risk factor for many cancers. Studies have shown a lower prevalence of smoking in cancer survivors. However, we wanted to determine whether this prevalence is constant or changes the longer the patient is cancer free. Methods: Data was obtained from NHANES III, a nationally representative health survey conducted from 1988-1994. Subjects who were diagnosed with solid tumors were included in this study. These subjects were divided into two groups, Group A(GpA) were those within 3 yrs of diagnosis of cancer and group B(GpB) included those more than 3 yrs from diagnosis of cancer. Prevalence of smoking in these groups was analyzed using the chi-square test (proc surveyfreq in SAS 9.3). Results: Of 33,994 subjects in the NHANES III database, 780 subjects were diagnosed with solid tumors. Of these, 415 subjects had data regarding their current smoking status. There were 138 subjects who were within 3 years and 183 subjects beyond 3 years of their cancer diagnosis. There were 38.1% males and 62% females, and 83%, 16% and 1% were white, black and other races, respectively. Current smoking in subjects without cancer was 52.3% and 30.1% in subjects with cancer which was consistent with prior studies. The cancer survivors within 3 years of diagnosis had a 22.4% (31/138) prevalence of smoking, and subjects with more than 3 years since diagnosis had a 34%(94/277) prevalence of smoking (p=0.01). (Table) Conclusions: The prevalence of smoking in cancer survivors was lower than in the general population as expected. Subjects who survived more than 3 yrs from their diagnosis had a statistically significant higher prevalence of smoking when compared to survivors less than 3 yrs from their diagnosis. Health care providers need to continue to counsel against smoking in cancer survivors for a longer period of time. Characteristics of cancer survivors. Variables Subj <3 yrs from cancer diagnosis (GpA) n=251 Subj >3 yrs from cancer diagnosis (GpB) n= 480 p-value Mean age (SD) 59.7 (1.62) 59.2 (1.22) Males 120 151 0.002 Females 131 321 Whites 189 415 0.0009 Blacks 57 63 Other races 5 2 Prevalence of smoking 22.4% 34% 0.01
Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.
Authors: Georg Pfeiler, Robert Konigsberg, Christian Fesl, Brigitte Mlineritsch, Herbert Stoger, Christian F. Singer, Sabine Poestlberger, Guenther G. Steger, Michael Seifert, Peter Christian Dubsky, Raimund Jakesz, Hellmut Samonigg, Vesna Bjelic-Radisic, Richard Greil, Christian Marth, Michael Gnant
Journal: Journal of Clinical Oncology (2012)

514 Background: Zoledronic acid (ZOL) improves disease outcome in premenopausal patients with breast cancer (BC), especially in those with low estrogen environment. Obesity is associated with increased estrogen serum levels, which might influence the efficacy of ZOL. We investigated the impact of BMI on the efficacy of ZOL in premenopausal patients with BC. Methods: ABCSG-12 examined the efficacy of ovarian suppression using goserelin (3.6 mg q28d SC) in combination with anastrozole (ANA) or tamoxifen (TAM) ± ZOL 4 mg IV q6mo) in premenopausal women with endocrine-responsive BC. BMI was calculated using the prospectively collected data on patients’ height and weight at study entry. BMI definitions of the WHO were used: normal 18.5-24.9 kg/m 2 , overweight: BMI 25-29.9 kg/m 2 , obese BMI ≥ 30 kg/m 2 ). Disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method and results were compared by using the log-rank test and Cox proportional hazard modeling. Results: Two thirds of the patients were normal weight (1,111) and one third was overweight (391) or obese (182). Normal weight patients treated with ZOL experienced the same benefit as overweight/obese patients treated with ZOL compared to patients without ZOL regarding disease free survival (HR 0.75, 95%CI 0.53 1.05 p = 0.09 and HR 0.71, 95%CI 0.46 1.1, p=0.12, respectively) as well as overall survival (HR 0.67, 95% CI 0.37 1.22, p=0.19 and HR 0.64, 95%CI 0.32 1.28, p=0.19, respectively). No difference regarding DFS and OS could be detected between normal weight and overweight/ obese patients treated with ZOL (HR 1.05, 95%CI 0.69 1.59, p=0.83 and HR 1.27, 95%CI 0.62 2.61, p= 0.51). Comparing normal weight patients with ZOL to obese patients with ZOL, again no difference could be observed. Conclusions: The significant outcome benefit of adjuvant zoledronic acid in ABCSG-12 can be demonstrated both in normal weight and overweight/obese premenopausal patients with early breast cancer, indicating that the bone marrow microenvironment changing impact of adjuvant bisphopshonate treatment does not correlate with patients’ BMI.
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting for gynecological cancer: KCOG G-1301 phase II trial.
Authors: Masakazu Abe, Yuka Kasamatsu, Kado Nobuhiro, Shiho Kuji, Aki Tanaka, Nobutaka Takahashi, Munetaka Takekuma, Yasuyuki Hirashima, Shin Nishio, Yoshio Itani, Yoshikazu Ichikawa, Yui Itonaga, Tomoko Hirakawa, Kaei Nasu, Kanoko Miyagi, Junko Murakami, Kimihiko Ito
Journal: Journal of Clinical Oncology (2015)

TPS9639 Background: Olanzapine is proved to be effective for chemotherapy-induced nausea and vomiting (CINV). But its preventive efficacy in combination with standard antiemetic therapy (palonosetron, aprepitant, and dexamethasone) is unknown. The purpose of this study is to prove the preventive effect of olanzapine for the prevention of CINV caused by highly emetogenic chemotherapy (HEC) when used with standard antiemetic therapy. We started a prospective multicenter phase II study at six facilities related to Kansai Clinical Oncology Group (KCOG) since September 2013. Methods: Chemo-naïve patients aged 20-79 years old is enrolled. They are gynecologic cancer patients who are treated with HEC regimen containing cisplatin (more than 50 mg/m2). Target sample size is 40. Since olanzapine is contraindicated in patients with diabetes mellitus, their blood sugar level and HbA1c are checked to confirm that they do not have glucose intolerance before treatment. All patients are informed of drug information and the consent of using olanzapine are obtained. Aprepitant is administered at a dose of 125 mg before chemotherapy on day 1 and at 80 mg on days 2 and 3. Palonosetron (0.75 mg) is given before chemotherapy on day 1. Dexamethasone is administered at a dose of 9.9 mg before chemotherapy on day 1 and at 6.6 mg on days 2–4. 5mg oral olanzapine is administered for 6 days from the day before chemotherapy. All of patients record the self-evaluation diary about their emesis every 24 h throughout the overall phase (0–120 h after cisplatin). The primary endpoint is the proportion of patients with a complete response (no vomiting and no rescue therapy) throughout the overall phase. The secondary endpoints are the proportion of patients with complete response in the acute phase (0–24 h after cisplatin) and in the delayed phase (24–120 h after cisplatin) of the study, as well as the proportion of patients with complete control (no vomiting, no rescue therapy, no significant nausea (numeric rating scale 0-2)) and total control (no vomiting, no rescue, no nausea) throughout the study and in the acute and delayed phases. Clinical trial information: UMIN000011857.
RISK OF INFECTIVE ENDOCARDITIS ASSOCIATED WITH CONCOMITANT PACEMAKER AMONG PATIENTS UNDERGOING AORTIC VALVE REPLACEMENT: A NATIONWIDE STUDY
Authors: Lauge Østergaard, Nana Valeur Køber, Lars Køber, Nikolaj Ihlemann, Henning Bundgaard, Gunnar Gislason, Christian Torp-Pedersen, Niels Eske Bruun, Emil Loldrup Fosbøl
Journal: Journal of the American College of Cardiology (2017)
DIAGNOSTIC UTILITY OF GOLDBERGER'S ELECTROCARDIOGRAPHIC TRIAD IN PREDICTING LEFT VENTRICULAR DYSFUNCTION IN CHAGAS’ HEART DISEASE
Authors: Diego Araiza Garaygordobil, Edgar Alexander Illescas González, Luis Marroquin Donday, Aloha Meave, Erick Alexanderson Rosas, Gabriela Melendez Ramirez
Journal: Journal of the American College of Cardiology (2017)
SURGICAL RISK SCORES OUTWEIGH ECHOCARDIOGRAPHIC SEVERITY OF AORTIC STENOSIS FOR DETERMINING PROGNOSIS IN PATIENTS WITH LOW GRADIENT SEVERE AORTIC STENOSIS AND PRESERVED LEFT VENTRICULAR FUNCTION
Authors: Yan Fan, Brandon Stacey, David Zhao, Robert Applegate, Sujethra Vasu, Bharathi Upadhya, Peter Flueckiger, Pallavi Gomadam, Min Pu
Journal: Journal of the American College of Cardiology (2017)
ALIROCUMAB TREATMENT IN A REAL WORLD SETTING: SAFETY UPDATE FROM AN OPEN-LABEL TREATMENT EXTENSION TO THE ODYSSEY PROGRAM FOR PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Authors: John R. Guyton, G. Kees Hovingh, Gisle Langslet, Robert Dufour, Marie Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, Michel Farnier
Journal: Journal of the American College of Cardiology (2017)
Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence.
Authors: Tanya Keenan, Beverly Moy, Edmund A Mroz, Kenneth Ross, Andrzej Niemierko, James William Rocco, Steven J. Isakoff, Leif W. Ellisen, Aditya Bardia
Journal: Journal of Clinical Oncology (2015)

6553 Background: Black Americans are much more likely to die from breast cancer (BC) than white Americans. While socioeconomic issues contribute to this disparity, the influence of genomics is unclear. We aimed to determine key genomic traits and their effect on BC recurrence. Methods: Whole exome sequencing and gene expression data collected between 2010 and 2014 on primary breast tumors were obtained from The Cancer Genome Atlas. Genomic profiles, including intratumor genetic heterogeneity measured by the mutant-allele tumor heterogeneity (MATH) algorithm, were compared by race with logistic regression models. Cox proportional hazard models evaluated the association of race, triple negative breast cancer (TNBC), mutations, MATH, and PAM50 subtype with risk of tumor recurrence. Results: A total of 609 white Americans and 102 black Americans were analyzed. Black Americans had significantly more TNBC than white Americans. Black Americans compared to white Americans had more TP53 mutations (43.1% vs 27.3%, p = 0.002) and fewer PIK3CA mutations (20.6% vs 34.0%, p = 0.01). MATH was greater (5.3 units, 95% CI 2.6 to 8.0, p < 0.001) in black Americans than in white Americans. Black Americans had a greater prevalence of the PAM50 basal subtype (40.2% vs 18.6%, p < 0.001) and a lower prevalence of the PAM50 luminal A subtype (10.8% vs 35.0%, p < 0.001) than white Americans. By Lehmann TNBC subtype, black Americans had more basal-like 1 tumors (25.9% vs 9.8%, p < 0.001). Of the 506 white Americans and 89 black Americans with follow up data, black Americans also had a higher risk of tumor recurrence than white Americans (Table). Separate adjustment for TP53 mutation, PAM50 subtype, and TNBC but not MATH decreased the magnitude and significance of the racial association with tumor recurrence. Conclusions: Besides having a higher prevalence of TNBC, BC in black American women had significantly greater TP53 mutations, intratumor genetic heterogeneity, PAM50 basal tumors, and TNBC basal-like 1 tumors, all of which are associated with more aggressive tumor biology. These genomic differences could contribute to racial disparities in BC outcomes. Hazard Ratio for Tumor Recurrence 95% CI p Black race (adjusted for age, stage) 2.22 (1.05, 4.67) 0.04 Black race additionally adjusted for MATH 2.19 (1.03, 4.64) 0.04 TP53 mutation 1.99 (0.94, 4.21) 0.07 TNBC 1.57 (0.72, 3.44) 0.26 PAM50 subtype 1.41 (0.64, 3.09) 0.39
Interleukin 8 Level, Reticulocyte Counting and aPTT Ratio in Brazilian Sickle Cell Anemia Patients with Leg Ulcers
Authors: Magnun N N Santos, Eliel Wagner Faber, Dulcinéia Martins Albuquerque, Romulo Tadeu Dias Oliveira, Marcos André Cavalcanti Bezerra, Carolina Lanaro, Tânia Regina Zaccariotto, Aderson S Araujo, Fernando Ferreira Costa, Maria Heloisa Souza Lima Blotta, Maria de Fátima Sonati
Journal: Blood (2011)
VARIATION IN INTRACORONARY LIPID-RICH PLAQUE DETECTED BY NEAR-INFRARED SPECTROSCOPY IN ASYMPTOMATIC INDIVIDUALS WITH HIGH CORONARY ARTERY CALCIUM SCORES
Authors: Jacob Bundy, Austin Clarey, Edwin Mandieka, Andrew LaCombe, David Benavides, Thomas Crane, Manivannan Veerasamy, Stacie Vanoosterhout, Abbey Mulder, Matthew Elmore, Ryan Madder
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF A PHARMACIST-PHYSICIAN COLLABORATIVE CARE MODEL TO STANDARD CARE ON THE TIME TO REACH GOAL BLOOD PRESSURE FOR PATIENTS PRESENTING WITH URGENT HYPERTENSION
Authors: Dave L. Dixon, Eric Parod, Evan Sisson, Benjamin Van Tassell, Pramit Nadpara, Heather Savage, Alan Dow, Daniel Carl
Journal: Journal of the American College of Cardiology (2017)
ADVANCES IN 3D ECHOCARDIOGRAPHY: AUTOMATED SOFTWARE IMPROVES THE LEARNING CURVE AND CLINICAL IMPLEMENTATION IN A REAL WORLD SETTING FOR QUANTITATIVE ASSESSMENT OF LEFT VENTRICULAR EJECTION FRACTION
Authors: Ronald B. Chin, Cassie Tighe, Timothy Beaver, Terrence Welch, Salvatore Costa
Journal: Journal of the American College of Cardiology (2017)
A multi-faceted strategy to reduce ventilation-associated mortality in brain-injured patients. The BI-VILI project: a nationwide quality improvement project
Authors: Karim Asehnoune, Ségolène Mrozek, Pierre François Perrigault, Philippe Seguin, Claire Dahyot-Fizelier, Sigismond Lasocki, Anne Pujol, Mathieu Martin, Russel Chabanne, Laurent Muller, Jean Luc Hanouz, Emmanuelle Hammad, Bertrand Rozec, Thomas Kerforne, Carole Ichai, Raphael Cinotti, Thomas Geeraerts, Djillali Elaroussi, Paolo Pelosi, Samir Jaber, Marie Dalichampt, Fanny Feuillet, Véronique Sebille, Antoine Roquilly
Journal: Intensive Care Medicine (2017)
Combination of Cytarabine and Topotecan Improves Response Rate for Patients Treated for Acute Myeloid Leukemia with Persistent Disease After Frontline Induction
Authors: Thomas Prebet, Estelle Jean, Aurelie Autret, Aude Charbonnier, Jerome Rey, Anne Etienne, Evelyne D'Incan, Sabine Furst, Christine Arnoulet, Didier Blaise, Norbert Vey
Journal: Blood (2011)
Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection
Authors: Antoine Sicard, Vannary Meas-Yedid, Maud Rabeyrin, Alice Koenig, Stephanie Ducreux, Frederique Dijoud, Valerie Hervieu, Lionel Badet, Emmanuel Morelon, Jean Christophe Olivo-Marin, Valerie Dubois, Olivier Thaunat
Journal: Kidney International (2017)
LEFT ATRIUM VOLUME INDEX MEASUREMENT IN ROUTINE PRACTICE: DOES IT INDEPENDENTLY IMPACT SURVIVAL OF DEGENERATIVE MITRAL VALVE DISEASE?
Authors: Clémence Antoine, Giovanni Benfari, Sorin Pislaru, David Messika-Zeitoun, Thierry Le Tourneau, Joseph F. Maalouf, Maurice Enriquez-Sarano
Journal: Journal of the American College of Cardiology (2017)
Phase I study of the antifolate pralatrexate given with vitamin B<sub>12</sub> and folic acid supplementation in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Authors: C. G. Azzoli, L. Krug, V. Miller, S. Bekele, L. Tyson, M. Dunne, M. Huntington, M. Saunders, M. G. Kris
Journal: Journal of Clinical Oncology (2007)

13006 Background: Pralatrexate is a novel antifolate that has shown promising activity in the treatment of pts with previously- treated NSCLC at doses of 135–150 mg/m 2 IV every other week (q2w). [Krug, Clin Cancer Res 9(6), 2003; 6(9), 2000] The addition of vitamin B 12 and folic acid supplementation may mitigate toxicity from pralatrexate and improve efficacy by allowing higher doses to be delivered. Methods: This study is designed to determine the maximum tolerated dose (MTD) of pralatrexate in combination with vitamin B 12 and folic acid supplementation in pts with NSCLC. Key eligibility criteria include confirmed stage IIIB or IV NSCLC; at least 1 prior chemotherapy regimen; Karnofsky performance status (KPS) = 70%; and no other active concurrent malignancy. Using a rapid escalation design, pralatrexate was initially administered at a dose of 150 mg/m 2 IV q2w, escalating by 40 mg/m 2 increments in successive cohorts, with one patient per cohort if no dose limiting toxicity (DLT) is encountered. All pts receive vitamin B 12 1 mg intramuscular q 8–10 weeks and folic acid 1 mg by mouth once a day beginning at least 7 days prior to pralatrexate. All patients undergo pharmacokinetic testing following their first and second dose of pralatrexate. Results: Between 1/05–12/06, a total of 9 pts have been treated at the following dose levels: 150 (n=1), 190 (n=1), 230 (n=1), and 270 (n=6). Patient characteristics include: 2 male/7 female; median age 63 (range 52–73); KPS 80–90%; all pts had stage 4 NSCLC; 5 pts received 1 prior regimen and 4 pts received 2 or more prior regimens. Grade 3 esophagitis was a DLT in one patient at the 270 mg/m 2 dose. Three other patients experienced grade 1–2 mucositis at this dose level without limiting drug delivery. The trial is ongoing, and enrollment is planned at 310 mg/m 2 q2w to determine the MTD. Conclusions: When given in combination with vitamin B 12 and folic acid supplementation, pralatrexate has been well tolerated in this pt population, with an MTD at least twice as high as achieved in previous phase 1 testing without supplementation. We plan to conduct a phase 2 trial of pralatrexate with vitamin B 12 and folic acid supplementation to see if a higher dose will improve efficacy. No significant financial relationships to disclose.
Do patient-reported quality-of-life responses in melanoma patients vary by stage?
Authors: Amanda Beth Cooper, Kate C. Griffin, Y. Sabrina Chiang, Merrick I. Ross, Jeffrey Edwin Lee, Jeffrey E. Gershenwald, Richard E. Royal, Anthony Lucci, Janice N. Cormier
Journal: Journal of Clinical Oncology (2014)

e20007 Background: Quality of life (QOL) has been shown to predict treatment response, health-related expenditures, work productivity, and mortality. The aim of this study was to examine differences in melanoma-associated QOL and their impact on survival. Methods: Data were pooled from 4 IRB-approved protocols; patients completed the FACT-Melanoma at study entry and ≥1 additional timepoint over a 12-month period. Quartile scores were evaluated based on response distributions and compared. A multinomial logistic regression model was created to report odds ratios (OR) and a longitudinal model evaluated QOL changes over time. Survival curves stratified by disease stage and high/low baseline QOL scores were constructed. Results: Of573 patients, 486 (85%) completed subsequent questionnaires; 340 (59%) had data at 12 months. At baseline, those with highest QOL scores compared to lowest quartile were more likely to be >65 years (OR 2.5 [1.2-5.1]), male (OR 2.1 [1.3-3.7]), and have an average household income >$46,000/year (OR1.7 [1.0-2.9]). Over time, QOL scores improved for stage I and decreased for stage IV patients; stage II-III patients demonstrated an initial post-treatment decrease with subsequent improvement. In the longitudinal model, stage IV had significant QOL decreases compared to stage I patients over time (OR 2.1 [1.1-3.9]). Income level (OR 0.7 [1.3-2.5]), receipt of systemic therapy (OR 1.9 [1.3-2.7]), and primary tumor location (OR 0.4 [0.2-0.7]) were also associated with QOL changes. Patients’ most frequent items of concern varied by disease stage: stage I-surgical scars (39%), stage II-melanoma progression (30%), stage III-post treatment swelling (90%), and stage IV-dying (46%). Lower baseline QOL scores were associated with poorer survival in patients with stage I/II disease (p<0.001) only. Conclusions: Female gender, poor socioeconomic status, lower extremity tumor location, higher disease stage, and systemic treatment were associated with decreased QOL. Time since treatment was independently associated with improved QOL. Strategies to improve baseline patient-reported QOL may have survival implications, particularly in stage I/II patients.
Cynomolgus Monkey Invariant NKT (iNKT) Cells Recover Following Depletion by Treatment with the Anti-Invariant T Cell Receptor Antibody NKTT120
Authors: Felix Scheuplein, Susan Macdonald, Brandon Zeigler, Elen LeBel, Abraham Thariath, Alem Truneh, Robert Mashal, David G. Nathan, Robert Schaub
Journal: Blood (2012)
Survival versus intrinsic and acquired resistance in advanced non-small cell lung cancer.
Authors: David J. Stewart, Pierre Saintigny, Glenwood D. Goss, Charles Lu
Journal: Journal of Clinical Oncology (2013)

e19066 Background: While advanced NSCLC responds to platinum-based therapy (PBT), intrinsic and acquired resistance limits efficacy. We assessed impact of resistance patterns on overall survival (OS). Methods: Using serial measurements of tumor diameters from 130 NSCLC patients on PBT, we calculated % incremental change in tumor size compared to the most recent prior scan and % overall change from pre PBT. Results: 98/130 (75%) had measurable tumor shrinkage (TS) at 1 st repeat scan (RS) post 2 cycles, of whom 81 had a 2 nd RS post 4 cycles. Of these, 20 (25%) had tumor growth (TG) at the 2 nd RS. Only 1 had initial TG then followed by TS. Of 41 with a 3 rd RS &lt;4 weeks post cycle 6, 13/41 (32%) had TG. The greatest % incremental TS (compared to most recent prior scan) was seen early (at 1 st RS) for 76% of patients. Rate of TS decreased with later cycles in these patients. 11 patients had rapid TS on 1 st RS, then gradual further shrinkage over &gt;3 subsequent scans, while 15 had progressive gradual TS over &gt;4 scans without initial rapid TS. By Spearman coefficients, maximum % TS from pre PBT over all scans correlated with OS (r=0.46, p&lt;0.0001), time to progression (TTP) (r=0.69, p&lt;0.0001) and post-progression survival (PPS) (r=0.30, p=0.001). TTP also correlated with OS (r=0.63, p&lt;0.0001), TTP correlated with PPS (r=0.44, p&lt;0.0001), and OS correlated with PPS (r=0.95, p&lt;0.0001). Median OS (11.0 months for all patients) varied with TS pattern (p&lt;0.0001): OS for patients with first TG at 1 st , 2 nd , 3 rd and 4 th RS was 5.9, 10.8, 10.5 and 15.1 months. OS was 18.2 months in patients with most TS at 1 st RS followed by gradual further TS over later scans, and was 30.5 months with progressive gradual TS without rapid TS at 1 st RS. OS with RECIST partial response (23% of patients), minor TS (52%), minor TG (13%) and RECIST progressive disease (13%) was 16.9, 12.4, 9.8 and 4.0 months (p&lt;0.0001). Conclusions: OS, TTP and PPS correlate strongly with response (degree of TS/TG) and with resistance pattern. OS is longest with progressive further TS over multiple scans. Within this group, partial acquired resistance (decreased TS rate after initial rapid TS) has shorter OS than with sustained incremental TS. The underlying biological factors driving clinical resistance remain undefined.
Preclinical Investigations Demonstrate Effectiveness of Aplidin in Acute Leukemias and Lymphomas and Provide the Basis for Further Clinical Studies.
Authors: Debabrata Banerjee, Guray Saydam, Lata G. Menon, Giuseppe S.A. Longo, Daniel Medina, Roger Strair, Jose Jimeno, Eugenio Erba, Alberto Grossi, Gertjan J.. L. Kapers, Norea Martinez, Joseph Bertino
Journal: Blood (2004)